The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.15 GBX | +7.50% | +4.88% | -67.91% |
May. 28 | NetScientific backs Wanda; Inspirit Energy wins deal | AN |
May. 10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-67.91% | 21.39M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |